- AbbVie raises profit forecast as immunology drugs continue to drive growth
- Micron Technology falls 5.7% in pre-market trading as Intel's guidance misses expectations
- Nokia drops 5.9% in pre-market trading; option prices are highly volatile, please pay attention to risks.
- Bernstein raises Starbucks target price to $115
- Imperial Oil Declares Fourth-Quarter Dividend of 87 Cents a Share
- Euro Holdings publishes 2026 annual report
- STARBUCKS CORP. <SBUX.O>: MORGAN STANLEY RAISES TARGET PRICE TO $116.00 FROM $115.00
- Royalindo Investa Wijaya Q3 2026 Liabilities Rise 28% on Higher Trade Payables
- ELI LILLY & CO. <LLY.N>: MORGAN STANLEY RAISES TARGET PRICE TO $1596.00 FROM $1430.00
- INTEL CORPORATION <INTC.O>: MORGAN STANLEY CUTS TARGET PRICE TO $75.00 FROM $84.00
- Era Media Sejahtera Total Liabilities Fall 60.67% at End-September
- AMAZON.COM INC : MORGAN STANLEY CUTS TARGET PRICE TO $335.00 FROM $350.00
- TECK RESOURCES LTD <TECK.N>: STONEX RAISES TARGET PRICE TO $72 FROM $67
- Euro Holdings Publishes 2026 Corporate Governance Report
- INTEL <INTC.O>: SUSQUEHANNA CUTS TARGET PRICE TO $75 FROM $105
- AVERY DENNISON CORP : RAYMOND JAMES RAISES TARGET PRICE TO $198 FROM $192
- RIVIAN <RIVN.O>: NEEDHAM CUTS TARGET PRICE TO $18 FROM $23
- Delta Resources Begins Maiden Drilling at I-Zone, Reports Additional Sampling Results at Delta-1 Gold Project
- AMAZON : RAYMOND JAMES CUTS TARGET PRICE TO $250 FROM $300
- BUZZ - Colgate-Palmolive shares rise after raising annual profit forecast
- Amazon falls 6.7% in pre-market trading; Q3 results and Q4 guidance below expectations
- AMD falls 8.4% in pre-market trading as Intel's guidance misses expectations, dragging down the semiconductor sector
- STRYKER CORPORATION <SYK.N>: NEEDHAM CUTS TARGET PRICE TO $359 FROM $418
- MAPLEBEAR INC. <CART.O>: RAYMOND JAMES CUTS TO MARKET PERFORM FROM OUTPERFORM
- Intel's fourth-quarter revenue and profit guidance falls short of expectations, shares drop 25.7% in pre-market trading
- ROBLOX CORPORATION <RBLX.N>: STONEX CUTS TARGET PRICE TO $32 FROM $33
- MERIT MEDICAL SYSTEMS INC <MMSI.O>: NEEDHAM RAISES TARGET PRICE TO $106 FROM $101
- UFP INDUSTRIES, INC. <UFPI.O>: STONEX CUTS TARGET PRICE TO $100 FROM $115
- Banco de Chile Q3 Earnings Fall, Operating Revenue Rises
- FIRST BUSEY CORPORATION <BUSE.O>: RAYMOND JAMES CUTS TO MARKET PERFORM FROM OUTPERFORM
- THERMO FISHER SCIENTIFIC INC. <TMO.N>: ARGUS RESEARCH RAISES TARGET PRICE TO $780 FROM $560
- ALPHATEC HOLDINGS, INC. : NEEDHAM CUTS TARGET PRICE TO $12 FROM $14
- AMAZON : STONEX CUTS TARGET PRICE TO $380 FROM $400
- Zcash grants group offers $124M compromise as governance backlash grows
- ALNYLAM PHARMACEUTICALS, INC. : RAYMOND JAMES CUTS TO OUTPERFORM FROM STRONG BUY; CUTS TARGET PRICE TO $315 FROM $420
- GILEAD <GILD.O>: NEEDHAM RAISES TARGET PRICE TO $200 FROM $170
- --LCI Industries Board Rejects Monomoy Capital's $101 per Share Acquisition Bid
- MASTERCARD <MA.N>: ARGUS RESEARCH RAISES TARGET PRICE TO $694 FROM $640
- Willis Lease Finance Raises Dividend, Renews Share Buyback Program
- WESCO INTERNATIONAL, INC. <WCC.N>: RAYMOND JAMES RAISES TARGET PRICE TO $420 FROM $400
- Bank Syariah Indonesia Plans Rights Issue of Up to 6,800,000,000 Shares
- Adaro Andalan Indonesia Liabilities Rise 20.25% to USD 2.47 Billion
- DFCITY Group publishes 2026 annual report
- DFCITY Seeks Renewal of Share Buyback Authority for Up to 10% of Issued Shares
- STARZ ENTERTAINMENT CORP. <STRZ.O>: RAYMOND JAMES RAISES TO STRONG BUY FROM OUTPERFORM; RAISES TARGET PRICE TO $36 FROM $35
- Metro Healthcare Indonesia Liabilities Rise 40.87% on Higher Sukuk Debt
- Aevex Wins $41.6 Million in Contracts for SightGlass, Fisher Systems
- --GUIDANCE: (ABBV) AbbVie Expects 2026 Adjusted EPS Range $13.95 to $13.99, vs. FactSet Est of $13.91
- OmniAb Raises 2026 Revenue and Cash Guidance
- DFCITY Group Publishes Corporate Governance Report
- Core AI Holdings Appoints Haggai Ravid to Board of Directors
- AbbVie Q3 EPS rises to $2.37; Q3 net revenues climb 10% to $17.4 billion
- Lindex wins appeal in Essity dispute over period underwear marketing
- AI Anxiety, French Tensions Pressure European Bourses Midday
- RBC Raises Price Target on Ligand Pharmaceuticals to $357 From $345, Keeps Outperform Rating
- GE VERNOVA INC. <GEV.N>: GLJ RESEARCH RAISES TARGET PRICE TO $540 FROM $470
- Intermedia Capital Changes Nov. 17 AGM Venue to Convergence Indonesia’s 28th Floor
- Sopharma shareholders approve EUR 0.068 per-share dividend at annual meeting
- BRIEF-AbbVie Inc Q3 Adjusted EPS USD 3.82 Vs. IBES Estimate USD 3.75
- -- Earnings Flash (ABBV) AbbVie Inc. Posts Q3 Adjusted EPS $3.82 per Share, vs. FactSet Est of $3.73
- PRISA Opens Sixth Debt Conversion Period Nov. 1-10, 2026
- ELI LILLY <LLY.N>: ARGUS RESEARCH RAISES TARGET PRICE TO $1,550
- AbbVie Had Seen 2026 Adjusted EPS $13.76 - $13.96 >ABBV
- AbbVie 3Q Global Botox Therapeutic Revenue $1.08B, Up 9.8% >ABBV
- AbbVie 3Q Global Vraylar Revenue $1.07B, Up 14.3% >ABBV
- Canadian National Railway Q3 Adjusted Earnings, Revenue Rise
- -- Earnings Flash (ABBV) AbbVie Inc. Reports Q3 Revenue $17.40B, vs. FactSet Est of $17.32B
- AbbVie Sees FY Adj EPS $13.95-Adj EPS $13.99 >ABBV
- AbbVie 3Q Global IMBRUVICA Rev $522M >ABBV
- AbbVie 3Q Global Skyrizi Rev $5.78B >ABBV
- AbbVie 3Q Adj EPS $3.82 >ABBV
- AbbVie 3Q U.S. HUMIRA Rev $372M >ABBV
- AbbVie 3Q EPS $2.37 >ABBV
- AbbVie 3Q Rev $17.4B >ABBV
- AbbVie 3Q Adj EPS $3.82 >ABBV
- AbbVie Raises 2026 View To Adj EPS $13.95-Adj EPS $13.99 >ABBV
- AbbVie Raises Quarterly Dividend to $1.82 From $1.73 >ABBV
- AbbVie 3Q Global Net Revenue From Immunology Portfolio $9.165B, Up 16.5% >ABBV
- AbbVie 3Q Global Rinvoq Revenue $2.71B, Up 23.9% >ABBV
- AbbVie 3Q Global Skyrizi Revenue $5.78B, Up 22.7% >ABBV
- AbbVie 3Q International HUMIRA Rev $311M >ABBV
- AbbVie 3Q Global Net Rev From Oncology Portfolio $1.7B >ABBV
- AbbVie 3Q Net $4.22B >ABBV
- AbbVie 3Q EPS $2.37 >ABBV
- AbbVie 3Q Global Humira Revenue $683M, Down 31.2% >ABBV
- AbbVie 3Q Global Net Revenue From Aesthetics Portfolio $1.18B, Down 1.4% >ABBV
- AbbVie 3Q Global Net Revenue From Oncology Portfolio $1.7B, Up 0.8% >ABBV
- AbbVie 3Q Global Net Revenue From Neuroscience Portfolio $3.39B, Up 19.4% >ABBV
- AbbVie 3Q Adjusted Gross Margin 85.1% >ABBV
- Allarity Therapeutics Secures First Lab Services Contract With European Biotech Company
- Vizsla Copper Completes Acquisition of Delta, Helm Bay Projects from Agnico Eagle
- Investors No Longer Cheering on AI Spending -- Market Talk
- OmniAb Raises 2026 View To Rev $35M-$39M >OABI
- Mammoth Energy Services 3Q EPS 1c >TUSK
- Lear 3Q Sales $5.77B >LEA
- General Dynamics 3Q Net $1.23B >GD
- Regeneron Pharma Now Sees 2026 Capital Spending $1.05B-$1.1B; Had Seen $1.03B-$1.1B >REGN
- BP's Balance Sheet Inflection Has Arrived -- Market Talk
- Regeneron Pharma Raises 2026 Adjusted R&D View to $6.05B-$6.15B >REGN
- Regeneron Pharma Now Sees 2026 Adjusted Gross Margin About 86%; Had Seen 84%-85% >REGN
